Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

N. Kochenderfer, James; Somerville, Robert; Lu, Tangying; Shi, Victoria; Bot, Adrian; M. Rossi, John; Xue, Allen; L. Goff, Stephanie; C. Yang, James; M. Sherry, Richard; A. Klebanoff, Christopher; S. Kammula, Udai; Sherman, Marika; Perez, Arianne; M. Yuan, Constance; Feldman, Tatyana; W. Friedberg, Jonathan; Roschewski, Mark; A. Feldman, Steven; McIntyre, Lori; Ann Toomey, Mary; A. Rosenberg, Steven

doi:10.1200/jco.2016.71.3024

Public

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

Published in Journal of Clinical Oncology • Mar 14, 2017

Authors:

James N. Kochenderfer

Robert Somerville

Tangying Lu

Abstract

Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy...

Subject

Medicine

Fludarabine

Lymphoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!